Incremental cost-effectiveness analysis of intravenous ganciclovir versus oral ganciclovir in the maintenance treatment of newly diagnosed cytomegalovirus retinitis in patients with AIDS

PharmacoEconomics

Volumn 16, Issue 1, 1999, Pages 71-84

  Rachlis, Anita ^a   Smaill, Fiona ^b   Walker, Valery ^c   Hotchkies, Lorraine ^c   Jones, Amy ^d  

^a UNIVERSITY OF TORONTO   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c i3 Global   (Canada)

^d Roche Global Pharmacoeconomic Res   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR; PLACEBO;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE COST; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; OPHTHALMOSCOPY; ORAL DRUG ADMINISTRATION; OUTPATIENT CARE; PHOTOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESOURCE MANAGEMENT; RETINITIS; TREATMENT INDICATION;

ADMINISTRATION, ORAL; ANTIVIRAL AGENTS; CANADA; COST-BENEFIT ANALYSIS; CYTOMEGALOVIRUS RETINITIS; GANCICLOVIR; HUMANS; INJECTIONS, INTRAVENOUS; RANDOMIZED CONTROLLED TRIALS; RETROSPECTIVE STUDIES;

EID: 0032812403     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199916010-00007     Document Type: Article

References (13)

1. 1. Drew WL, Ives D, Lalexari JP, et al. Oral ganciclovir as maintenance therapy for cytomegalovirus retinitis in patients with AIDS. N Engl J Med 1995; 333: 615-20
2. 2. The Oral Ganciclovir European and Australian Cooperative Study Group. Intravenous versus oral ganciclovir: European/Australian comparative study of efficacy and safety in the prevention of cytomegalovirus retinitis recurrence in patients with AIDS. AIDS 1995; 9: 471-7
3. 3. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1997; 337: 725-33
4. 4. Statistics Canada. Consumer prices and price indexes, April-June 1995 (catalogue no. 62-010, vol. 21, no. 2). Ottawa (ON): Ministry of Industry, 1995
5. 5. Ontario Ministry of Health. Schedule of benefits, physician services under the Health Insurance Act. Ontario: Ministry of Health, 1992
6. 6. 1993/1994 Chedoke-McMaster Corporate Cost Model. Hamilton (ON): Health Care Economics, Centre for Evaluation of Medicine, 1995
7. 7. Statistics Canada. Average weekly earnings industrial aggregate. Ottawa (ON): Statistics Canada, 1994
8. 8. Ontario Ministry of Health. Drug benefit formulary no. 34: comparative drug index. Toronto (ON): Ministry of Health, 1994
9. 9. 1995 Drug Topics Red Book. Montvale (NJ): Medical Economics Co. Inc., 1995
10. 10. Sullivan SD, Mozaffari E, Johnson ES, et al. An economic evaluation of oral compared with intravenous ganciclovir for maintenance treatment of newly diagnosed cytomegalovirus retinitis in AIDS patients. Clin Ther 1996; 18: 546-58
11. 11. von den Schulenburg JG, Wahling S, Stoll M. German health economic cost evaluation on oral ganciclovir in treating cytomegalovirus retinitis. Pharmacoeconomics 1996; 10 (5): 522-30
12. 12. Davies L, Maynard A. An economic exploration of oral and intravenous ganciclovir in the induction and maintenance treatment of AIDS-related cytomegalovirus retinitis. Int J STD AIDS 1996; 7: 415-21
13. 13. Johnson ES, Sullivan SD, Mozaffari E, et. al. A utility assessment of oral and intravenous ganciclovir for the maintenance treatment of AIDS-related CMV retinitis. Pharmacoeconomics 1996; 10 (6): 623-9